logo

ABVC

ABVC BioPharma·NASDAQ
--
--(--)
--
--(--)
3.41 / 10
Netural

Fundamental breakdown reveals weak profile (3.4/10). Supportive elements: Interest coverage ratio (EBIT / Interest expense) (%) and Asset-MV, although drawbacks are visible in PB-ROE and Days sales outstanding. This suggests selective positioning.

Fundamental(3.41)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.64
Score3/3
Weight18.84%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value56.80
Score2/3
Weight1.61%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.07%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight15.02%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight15.04%
1M Return8.45%
PB-ROE
Value1.39
Score1/3
Weight18.29%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value56.80
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.37%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight14.77%
1M Return8.41%
Is ABVC fundamentally strong?
  • ABVC scores 3.41/10 on fundamentals and holds a Fair valuation at present. Backed by its -57.12% ROE, -671.88% net margin, -8.33 P/E ratio, 2.92 P/B ratio, and -211.11% earnings growth, these metrics solidify its Netural investment rating.